Credit Suisse Ag Surface Oncology, Inc. Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$1.05 - $2.1 $19 - $39	-19 Reduced 0.05%	40,000 $42,000
Q2 2022 Aug 12, 2022	SELL	$1.42 - $3.15 $3,832 - $8,501	-2,699 Reduced 6.32%	40,019 $66,000
Q1 2022 May 16, 2022	SELL	$2.65 - $5.08 $5,819 - $11,155	-2,196 Reduced 4.89%	42,718 $126,000
Q4 2021 Feb 14, 2022	BUY	$4.73 - $7.9 $212,443 - $354,820	44,914 New	44,914 $214,000
Q4 2020 Feb 12, 2021	SELL	$6.87 - $10.48 $171,853 - $262,157	-25,015 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$5.06 - $7.23 $126,575 - $180,858	25,015 New	25,015 $173,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.